Last reviewed · How we verify
NCT04811508: CARMYN
Retrospective Study to Describe Carfilzomib Use on Patients With Relapsed Multiple Myeloma in France in the Context of Carfilzomib Nominative Expanded Access and Compassionate Use
trial in Relapsed Multiple Myeloma in 172 participants. Completed in 31 December 2021.
31 December 2021
Quick facts
| Lead sponsor | Centre Hospitalier le Mans |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 172 |
| Start date | 4 August 2020 |
| Primary completion | 31 December 2021 |
| Estimated completion | 31 December 2021 |
| Sites | 1 location across France |
Conditions studied
- Relapsed Multiple Myeloma — all drugs for Relapsed Multiple Myeloma →
Sponsor
Centre Hospitalier le Mans
Who can join
18 and older, any sex, with Relapsed Multiple Myeloma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This retrospective multicenter observational study will provide real-life efficacy and tolerance data for patients with relapsed multiple myeloma (RMM) treated with carfilzomib in the context of nominative expanded access and compassionate use in France, and will allow to evaluate healthcare practices from data obtained during the use of carfilzomib for routine care. Nominative expanded access was open in February 2014 and stopped in march 2016, then relayed by the compassionate program (march 2016- February 2017).
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Interplay between proteasome inhibitors and NF-κB pathway in leukemia and lymphoma: a comprehensive review on challenges ahead of proteasome inhibitors.
Pakjoo M, Ahmadi SE, Zahedi M, Jaafari N, et al · · 2024 · cited 24× · PMID 38331801 · DOI 10.1186/s12964-023-01433-5
Verify or expand the search:
- PubMed search for NCT04811508
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Relapsed Multiple Myeloma
Currently open trials in the same condition.
- NCT06348108 — Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma · Phase 1 · recruiting
- NCT05896228 — Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma · Phase 2 · recruiting
- NCT06119685 — IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers · Phase 1, PHASE2 · recruiting
- NCT05577000 — Anti-BCMA Chimeric Antigen Receptor T Cells for Relapsed or Refractory Multiple Myeloma · Phase 1 · active not recruiting
- NCT04965155 — A Trial for Relapsed Multiple Myeloma Patients (Isatuximab-dexamethasone) · Phase 2 · active not recruiting
Other Centre Hospitalier le Mans trials
Trials by the same sponsor.
- NCT07365644 — Prophylactic ANTicoagulation With HEparine in Critically Ill Patients With Renal Impairment · not yet recruiting
- NCT07301957 — Impact of Early Rupture of the Residual Membrane on Latency Before Labour Begins · NA · not yet recruiting
- NCT07458477 — Digital Audiometer vs. Conventional Audiometer (Gold Standard): Study of Tonal and Vocal Recognition Thresholds · NA · recruiting
- NCT06799806 — The Impact of the Therapeutic Virtual Reality Headset on Patient Anxiety in the Waiting Room Before Flexible Bronchoscop · NA · recruiting
- NCT05915663 — Impact of the Choice of Gastric Tube Placement Sites on the Incidence of Ventilator Associated Pneumonia · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04811508 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Centre Hospitalier le Mans
- Last refreshed: 9 March 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04811508.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing